{"cluster": 58, "subcluster": 8, "abstract_summ": "Results We included 40 studies on CP treatment for infectious diseases We found that CP treatment could reduce the risk of mortality with a low incidence of adverse events, promote the production of antibodies, show the decline in viral load, and shorten the disease course.To explore the effectiveness of treatment and predict the potential effect of CP for COVID-19, studies of different types of infectious diseases treated with CP were included in this systematic review and meta-analysis.INTERPRETATION Studies of non- COVID-19 severe respiratory viral infections provide indirect, very low-quality evidence that raises the possibility that convalescent plasma has minimal or no benefit in the treatment of COVID-19 and low-quality evidence that it does not cause serious adverse events.Besides, 10-day treatment regimen overpowers 5-day treatment and placebo in decreasing time to clinical improvement.A meta-analysis of 15 controlled studies showed that there was a significantly lower mortality rate in the group treated with CP (pooled OR = 0.32, 95% CI: 0.19-0.52, P < 0.001, I2 = 54%) than in the control groups.", "title_summ": "Remdesivir Efficacy in Coronavirus Disease 2019 (COVID-19): A Systematic ReviewEfficacy of remdesivir versus placebo for the treatment of COVID-19: A protocol for systematic review and meta-analysis of randomized controlled trialsRemdesivir use in patients with coronavirus COVID-19 disease: a systematic review and meta-analysisComparative efficacy of the front-line anti-HBV drugs in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and network meta-analysisEfficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trialsPotential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapyEfficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.", "title_abstract_phrases": "PROSPERO REGISTRATION NUMBER: CRD42020177953.Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapyAbstract Background Convalescent plasma (CP) has been used successfully to treat many types of infectious diseases, and it has shown initial effects in the treatment of the emerging 2019 coronavirus disease (COVID-19).To explore the effectiveness of treatment and predict the potential effect of CP for COVID-19, studies of different types of infectious diseases treated with CP were included in this systematic review and meta-analysis.Results We included 40 studies on CP treatment for infectious diseases We found that CP treatment could reduce the risk of mortality with a low incidence of adverse events, promote the production of antibodies, show the decline in viral load, and shorten the disease course.INTERPRETATION Studies of non- COVID-19 severe respiratory viral infections provide indirect, very low-quality evidence that raises the possibility that convalescent plasma has minimal or no benefit in the treatment of COVID-19 and low-quality evidence that it does not cause serious adverse events.Systematic review, Meta-analysis, protocolRemdesivir use in patients with coronavirus COVID-19 disease: a systematic review and meta-analysisBackground Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2, has led to significant global mortality and morbidity."}